Trade Summary

1 week ago, Hohl Benjamin, serving as CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 6,018 shares at $52.64 per share, for a total transaction value of $316,780.33. Following this transaction, Hohl Benjamin now holds 46,054 shares of ELVN.

This sale represents a 11.56% decrease in Hohl Benjamin's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, July 17, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, July 21, 2026 at 5:24 PM ET, 4 days after the trade was made.

Enliven Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.